Chronic Kidney Disease (CKD) Drugs Market Projected to Reach USD 19.22 Billion by 2030, Driven by Rising Prevalence and Advancements in Treatment

TheChronic Kidney Disease (CKD) Drugs Market Growth is experiencing significant growth, with projections indicating an expansion from USD 13.13 billion in 2023 to approximately USD 19.22 billion by 2030. This growth, at a compound annual growth rate (CAGR) of 5.6%, is attributed to the increasing prevalence of CKD, advancements in treatment options, and heightened awareness of early diagnosis.

Request a Free Sample of the Report for Detailed Insights! https://www.maximizemarketresearch.com/request-sample/39171/ 

Market Estimation & Definition

Chronic Kidney Disease is a progressive condition characterized by the gradual loss of kidney function over time. It affects the body's ability to filter waste and excess fluids, leading to various health complications. The CKD drugs market encompasses a range of medications aimed at slowing disease progression, managing symptoms, and treating associated conditions.​

Market Growth Drivers & Opportunities

Key factors propelling the CKD drugs market include:

  • Increasing Prevalence of CKD: Approximately 15% of adults in the United States, equating to around 37 million individuals, are affected by CKD. Globally, over 850 million people were estimated to have kidney disease in 2020. The growing burden of CKD is anticipated to make it the fifth leading cause of years of life lost by 2040.

  • Advancements in Treatment: The development of novel therapies and the approval of new drugs are enhancing treatment efficacy and patient outcomes. Pharmaceutical companies are investing in research to address unmet needs in CKD management.​

  • Rising Awareness and Early Diagnosis: Increased public health initiatives and education campaigns are promoting early detection and management of CKD, leading to better patient prognosis and increased demand for effective treatments.​

Segmentation Analysis

The CKD drugs market is segmented based on drug class and end-user:​

  • By Drug Class:

    • Angiotensin-Converting Enzyme (ACE) Inhibitors: Commonly used to manage hypertension and slow CKD progression.

    • Angiotensin II Receptor Blockers (ARBs): Alternative to ACE inhibitors, particularly for patients experiencing side effects.

    • Calcium Channel Blockers: Effective in controlling blood pressure in CKD patients.

    • Beta Blockers: Used to manage cardiovascular complications associated with CKD.

    • Erythropoiesis-Stimulating Agents (ESAs): Address anemia, a common CKD complication.

    • Diuretics: Help manage fluid overload in CKD patients.

    • Others: Includes phosphate binders, vitamin D analogs, and more.​

  • By End-User:

    • Hospitals: Primary centers for CKD diagnosis and treatment.

    • Specialty Clinics: Offer specialized care for CKD patients.

    • Others: Includes home care settings and dialysis centers.​

Country-Level Analysis

  • United States: The U.S. holds a significant share of the CKD drugs market, driven by a high prevalence of CKD, advanced healthcare infrastructure, and substantial investment in research and development.​

  • Germany: Germany represents a key market in Europe, with a strong focus on early diagnosis and comprehensive CKD management programs contributing to market growth.​

Competitive Landscape

The CKD drugs market is characterized by the presence of several key players actively engaged in research, development, and strategic collaborations to enhance their market position. Notable companies include:​

  • AstraZeneca

  • Amgen Inc.

  • Hoffmann-La Roche Ltd.

  • Pfizer, Inc.

  • Sanofi

  • GlaxoSmithKline plc (GSK)

  • AbbVie Inc.

  • Keryx Biopharmaceuticals, Inc.

  • Kissei Pharmaceutical Co., Ltd.

  • Regeneron Pharmaceuticals, Inc.

  • Bayer AG

  • Reata Pharmaceuticals, Inc.

  • Ardelyx, Inc.

  • Boehringer Ingelheim International GmbH

  • Novo Nordisk A/S

  • Novartis AG

  • Johnson & Johnson

  • Astellas Pharma Inc.

  • Takeda Pharmaceutical Company Limited

  • Akebia Therapeutics, Inc. ​

Conclusion

The global CKD drugs market is poised for substantial growth, driven by the increasing prevalence of CKD, advancements in treatment options, and heightened awareness of early diagnosis. Stakeholders in the healthcare industry are encouraged to invest in research and development to further improve treatment outcomes and address the growing burden of CKD worldwide.​

To explore More Reports, visit our website:

Global Mesenchymal Stem Cells Market https://www.maximizemarketresearch.com/market-report/global-mesenchymal-stem-cells-market/114507/ 

Global Veterinary Surgical Instruments Market https://www.maximizemarketresearch.com/market-report/global-veterinary-surgical-instruments-market/7743/ 

Synthetic Blood Substitutes and Blood Product Market https://www.maximizemarketresearch.com/market-report/synthetic-blood-substitutes-and-blood-product-market/137359/ 

Synthetic Biology Market North America Forecast (20192026) https://www.maximizemarketresearch.com/market-report/synthetic-biology-market-north-america/1629/ 

 

About Maximize Market Research:

Maximize Market Research is a versatile market research and consulting firm with expertise across a wide range of industries. Our coverage includes medical devices, pharmaceutical manufacturing, science and engineering, electronic components, industrial equipment, technology and communication, automotive, chemicals, general merchandise, beverages, personal care, and automated systems, among others. We offer a comprehensive suite of services, including market-validated industry estimates, technical trend analysis, in-depth market research, strategic consulting, competitive analysis, production and demand evaluation, and client impact studies.

Contact Maximize Market Research:

Address :

3rd Floor, Navale IT Park, Phase 2

Pune-Bangalore Highway, Narhe

Pune, Maharashtra 411041, India

Email: [email protected]

Phone: +91 96071 95908, +91 9607365656